LeMaitre Vascular, Inc.
HealthcareNASDAQ:LMAT · NASDAQ Global Market
-$0.38 today
Vol 0.21M · Avg 0.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.7%
avg 12.3%
ROIC
9.0%
avg 10.6%
ROA
9.4%
avg 9.8%
Analysis
ROE is currently the strongest return metric at 14.7% versus its period average of 12.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
George W. LeMaitre | Chairman & Chief Executive Officer | $1.68M | — | 61 | $1.42M | 6.21% |
Dorian LeBlanc | Chief Financial Officer | $789,175.00 | — | 51 | $13.90 | <0.01% |
David Roberts | President & Director | $706,346.00 | — | 62 | $28.03 | <0.01% |
Trent G. Kamke | Senior Vice President of Operations | $565,568.00 | — | 55 | $12.81 | <0.01% |
George D. LeMaitre FACS | Founder and Chairman of Scientific Advisory Board | $118,482.00 | — | 92 | $1.42M | 6.21% |
Daniel J. Mumford | Senior Director of Human Resources | — | — | 44 | — | — |
Jonathan W. Ngau | Senior Vice President of Information Technology | — | — | 52 | — | — |
Maik D. Helmers | Senior Vice President of Sales Central Europe | — | — | 52 | — | — |
Ryan H. Connelly | Senior Vice President of Advanced Manufacturing Engineering | — | — | 49 | — | — |
Kimberly L. Cieslak | Vice President of Marketing | — | — | 53 | — | — |
Laurie A. Churchill | Chief Legal Officer | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$30.04M
Net Sentiment
$30.04M
Net selling
Most Active
LeMaitre George W
4 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $30.04M over the last 12 months. That adds up to net selling of $30.04M. LeMaitre George W was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +37.9% | N/A2 analysts |
| Revenue | N/A | N/A | +11.4% | +11.3% (14yr)3 analysts |
| Net Income | N/A | N/A | +44.5% | N/A3 analysts |
| EBIT | N/A | N/A | +39.5% | +15.2% (14yr)3 analysts |
Analysis
Recent growth has been strongest in Net Income at +44.5% over three years. Forward estimates point to EBIT at +15.2% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$4.74B
Haemonetics Corporation
NYSE:HAE
$3.55B
National HealthCare Corporation
AMEX:NHC
$3.09B
Acadia Healthcare Company, Inc.
NASDAQ:ACHC
$2.26B
Aveanna Healthcare Holdings Inc.
NASDAQ:AVAH
$1.54B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.46B
AtriCure, Inc.
NASDAQ:ATRC
$1.46B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Inspire Medical Systems, Inc.
NYSE:INSP
$1.23B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
Who manages LMAT?
LeMaitre Vascular, Inc. (LMAT) lists 11 active executives. The top listed executive is David Roberts, President & Director.
Are LMAT insiders buying or selling?
Recent insider activity shows net selling of $30.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.